Brief: Celcuity Announces First Patient Dosed In Phase 3 Viktoria-2 Clinical Trial Of Gedatolisib
24/07/2025 21:18
July 24 (Reuters) - Celcuity Inc CELC.O: CELCUITY ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 VIKTORIA-2 CLINICAL TRIAL OF GEDATOLISIB AS A FIRST-LINE TREATMENT FOR HR+/HER2- ADVANCED BREAST CANCER Source text: ID:nGNXShkzv Further company coverage: CELC.O ((Reuters.Briefs@thomsonreuters.com;))